NASDAQ:INVA - Innoviva Stock Price, Price Target & More

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Innoviva Inc (NASDAQ:INVA) released its quarterly earnings data on Thursday, April, 26th. The biotechnology company reported $0.27 EPS for the quarter, missing analysts' consensus estimates of $0.50 by $0.23. The biotechnology company earned $52.40 million during the quarter, compared to analyst estimates of $71.84 million. Innoviva had a negative return on equity of 63.57% and a net margin of 64.11%. The company's quarterly revenue was up 29.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.19 EPS. View Innoviva's Earnings History.

Innoviva is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Innoviva.

6 brokerages have issued 1 year price objectives for Innoviva's stock. Their predictions range from $8.00 to $16.00. On average, they expect Innoviva's stock price to reach $13.20 in the next year. This suggests that the stock has a possible downside of 11.5%. View Analyst Ratings for Innoviva.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Innoviva include Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), United Therapeutics (UTHR), Loxo Oncology (LOXO), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE) and Array Biopharma (ARRY).

News stories about INVA stock have trended somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Innoviva earned a daily sentiment score of 0.20 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 46.13 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Innoviva's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Campbell & CO Investment Adviser LLC (0.04%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, Michael W Aguiar, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva.

INVA stock was bought by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Innoviva.

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of INVA stock can currently be purchased for approximately $14.91.

Innoviva has a market capitalization of $1.52 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.17 on an earnings per share basis. Innoviva employs 12 workers across the globe.

Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]